DT 5461

structure given in first source; DT-5461a is the monomeglumine salt

Also Known As:

1,3-dicarboxyisopropyl-2-deoxy-6-O-(2-deoxy-3-O(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-beta-D-glucopyranosyl)-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-alpha-D-glucopyranoside; DT-5461; DT-5461a; Pentanedioic acid, 3-((2-deoxy-6-O-(2-deoxy-3-O-(((1-oxododecyl)amino)acetyl)-2-((1-oxotetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)-3-O-(((1-oxododecyl)amino)acetyl)-2-((1-oxotetradecyl)amino)-alpha-D-glucopyranosyl)oxy)-

Networked: 13 relevant articles (5 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 04/01/1995 - "A systemic single administration of DT-5461 caused a marked decrease in the number of vessels oriented toward the tumor mass and in the tumor size during the early phase of vasculogenesis (on day 4 after tumor inoculation), with little or no inhibition in the following phases. " 01/01/1997 - "Meanwhile, a weaker therapeutic efficacy of DT-5461 was observed against certain tumors that caused a significant increase in the level of immunosuppressive factors in host blood. " 01/01/1997 - "In the present study, DT-5461 also exhibited significant antitumor effects against 5 out of 6 human tumor xenografts in nude mice. " 01/01/1995 - "In this study, we investigated the effect of DT-5461a on regional blood flow in various organs including tumor tissue with a radiolabeled tracer-distribution technique using 14C-iodoantipyrine. " 01/01/1997 - "These findings support the idea that intratumoral TNF plays a crucial role in the antitumor mechanisms of DT-5461 and suggest that its antitumor action is influenced by an augmentative effect of tumor cells on TNF production and by blood levels of immunosuppressive factors."
2.	Infections 09/01/1994 - "Therefore, these immunomodulating activities presented by DT-5461 caused protection against Sendai virus infection." 08/01/1993 - "The injection of DT-5461 6 h in advance could also confer protection against the infection. " 09/01/1994 - "Intranasal (i.n.) administration of 200 micrograms of DT-5461 per mouse 3 days before infection was the most effective administration route, dose and timing. " 09/01/1994 - "DT-5461 enhanced host resistance to Sendai virus infection in mice. " 09/01/1994 - "Effect of the synthetic lipid A-related compound, DT-5461, on resistance to Sendai virus infection in mice."
3.	Neoplasm Metastasis (Metastasis) 10/01/1992 - "Four intermittent i.v. administrations of DT-5461 at intervals of 4 days resulted in a significant inhibition of liver metastasis caused by i.v. injection of L5178Y-ML25 cells and lung metastasis of B16-BL6 cells in the experimental metastasis models. " 04/01/1995 - "These results suggested that the suppressive effect upon tumor-associated angiogenesis by DT-5461 contributes in part to the inhibition of tumor metastasis." 04/01/1995 - "Multiple i.v. administrations of DT-5461 at intervals of 4 days (an effective schedule for inhibiting tumor metastasis) significantly reduced the number of capillary vessels and tumor growth over a period of 14 days after the tumor implantation. " 10/01/1992 - "These results suggested that DT-5461 may be therapeutically useful for the inhibition of tumor metastasis." 10/01/1992 - "Intraperitoneal and intranasal administrations as well as i.v. administration of DT-5461 were also effective in preventing lung metastasis of the melanoma cells. "
4.	Melanoma (Melanoma, Malignant) 10/01/1992 - "Furthermore, the group that received DT-5461 after the inoculation of lymphoma or melanoma cells showed significantly enhanced survival rate compared with the untreated control. " 10/01/1992 - "Multiple administrations of DT-5461 before the surgical excision of primary tumors significantly reduced the number of lung colonies of melanoma cells and primary tumor size. " 04/01/1995 - "We investigated the effect of a synthetic lipid A analogue with low endotoxicity, DT-5461, on the neovascularization induced by B16-BL6 melanoma in syngeneic mice. " 10/01/1992 - "Intraperitoneal and intranasal administrations as well as i.v. administration of DT-5461 were also effective in preventing lung metastasis of the melanoma cells. " 10/01/1992 - "We have investigated the antimetastatic effect of a new synthetic lipid A analogue, of low endotoxicity, DT-5461, against two highly metastatic tumor cell lines, L5178Y-ML25 T-lymphoma and B16-BL6 melanoma cells in mice. "
5.	Necrosis 06/01/1999 - "In14-day intravenous toxicity studies of DT-5461, rats were more susceptible to hepatocellular necrosis and splenomegaly than squirrel monkeys. " 01/01/1995 - "We previously reported that a synthetic low-toxicity lipid A analog, DT-5461a, exhibited a significant antitumor effect was characteristically accompanied by extensive tumor necrosis, suggesting that DT-5461a causes a local circulatory disturbance in tumor tissues. " 01/01/1992 - "Intravenous injection of DT-5461 into mice transplanted with solid tumors of MethA fibrosarcoma, MH134 hepatoma, MM46 mammary carcinoma, Lewis lung carcinoma (3LL), and colon adenocarcinomas 26 and 38 resulted in significant reductions in the weight of all tumors except Colon 26, with marked hemorrhagic necrosis of tumor tissues. "

Related Drugs and Biologics

1.	Lipid A
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Dinoprostone (PGE2)
4.	Messenger RNA (mRNA)
5.	Lipopolysaccharides
6.	Interleukin-1 (Interleukin 1)
7.	Interferons
8.	Indomethacin (Indometacin)
9.	Dacarbazine (DIC)
10.	Antineoplastic Agents (Antineoplastics)

Related Therapies and Procedures

1.	Intranasal Administration
2.	Intravenous Administration
3.	Therapeutics
4.	Lasers (Laser)
5.	Intravenous Injections